-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Rheumatoid Arthritis (RA) is a chronic autoimmune disease.
A variety of immune cells and signal networks fail, the tissue repair process is disordered, and joints, lungs, blood vessels and other damages occur.
Rheumatoid arthritis has a long cycle and the first stage is usually asymptomatic.
It is characterized by the production of autoantibodies against post-translationally modified proteins (usually citrullinated antigens).
This state can last from several years to decades.
Eventually, some people enter the stage with obvious symptoms and develop synovitis (acute joint inflammation turns into chronic destructive synovitis).
The tissue response is a poorly adapted wound healing response, and pannus is formed, leading to irreversible Tissue damage (tendon, cartilage, bone, etc.
).
The evolution of rheumatoid arthritis in a lifetime (Nature Immunology, https://doi.
org/10.
1038/s41590-020-00816-x) Finding the molecular profile of early treatment response is a key issue for precise treatment of RA.
Scientists from Queen Mary University of London, University of Cambridge reported their work in this area: Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes.
Researchers first identify early RA patients through multiple clinical indicators (clinical disease activity, blood testing, ultrasound, X-ray, etc.
), and obtain tissue samples through ultrasound-guided synovial biopsy.
Through classical histopathological section, synovial blood RNA sequencing to determine subgroups, and finally to determine the molecular characteristics of patients who responded and did not respond to treatment.
The author found that the transcriptional subgroups in the synovium are related to three different pathological types: fibroblastic pauci-immune, and macrophage-rich diffuse myeloid.
, Lympho-myeloid pathological type characterized by high plasma cells (lympho-myeloid).
Studies have shown that the pathological subtype of hyperplasma cell lymphoid myeloid is a subgroup with poor prognosis and progressive tissue structural damage.
Research results synovial RNA sequencing and early rheumatoid arthritis early pathology-related rheumatoid arthritis synovitis cell specific gene module clinical radiology correlation synovial and blood RNA-Seq comparison reveals the differential axis of gene expression Clustering and signal pathway analysis of different expressed genes in rheumatoid arthritis synovitis.
RNA-Seq and 6-month DMARD treatment response correlation 360 comments: Type I interferon-related genes, TLR, PI3K-related signaling pathway genes are up-regulated and involved in induction The type of lymphoid myeloid pathology characterized by hyperplasma cells is a factor of poor treatment effect and poor prognosis.
Main references Cornelia M Weyand and Jörg J Goronzy, The immunology of rheumatoid arthritis, Nature Immunology, Nat Immunol.
2021 Jan;22(1):10-18.
Myles J.
Lewis et al, Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes,, Cell Reports 28, 2455–2470
A variety of immune cells and signal networks fail, the tissue repair process is disordered, and joints, lungs, blood vessels and other damages occur.
Rheumatoid arthritis has a long cycle and the first stage is usually asymptomatic.
It is characterized by the production of autoantibodies against post-translationally modified proteins (usually citrullinated antigens).
This state can last from several years to decades.
Eventually, some people enter the stage with obvious symptoms and develop synovitis (acute joint inflammation turns into chronic destructive synovitis).
The tissue response is a poorly adapted wound healing response, and pannus is formed, leading to irreversible Tissue damage (tendon, cartilage, bone, etc.
).
The evolution of rheumatoid arthritis in a lifetime (Nature Immunology, https://doi.
org/10.
1038/s41590-020-00816-x) Finding the molecular profile of early treatment response is a key issue for precise treatment of RA.
Scientists from Queen Mary University of London, University of Cambridge reported their work in this area: Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes.
Researchers first identify early RA patients through multiple clinical indicators (clinical disease activity, blood testing, ultrasound, X-ray, etc.
), and obtain tissue samples through ultrasound-guided synovial biopsy.
Through classical histopathological section, synovial blood RNA sequencing to determine subgroups, and finally to determine the molecular characteristics of patients who responded and did not respond to treatment.
The author found that the transcriptional subgroups in the synovium are related to three different pathological types: fibroblastic pauci-immune, and macrophage-rich diffuse myeloid.
, Lympho-myeloid pathological type characterized by high plasma cells (lympho-myeloid).
Studies have shown that the pathological subtype of hyperplasma cell lymphoid myeloid is a subgroup with poor prognosis and progressive tissue structural damage.
Research results synovial RNA sequencing and early rheumatoid arthritis early pathology-related rheumatoid arthritis synovitis cell specific gene module clinical radiology correlation synovial and blood RNA-Seq comparison reveals the differential axis of gene expression Clustering and signal pathway analysis of different expressed genes in rheumatoid arthritis synovitis.
RNA-Seq and 6-month DMARD treatment response correlation 360 comments: Type I interferon-related genes, TLR, PI3K-related signaling pathway genes are up-regulated and involved in induction The type of lymphoid myeloid pathology characterized by hyperplasma cells is a factor of poor treatment effect and poor prognosis.
Main references Cornelia M Weyand and Jörg J Goronzy, The immunology of rheumatoid arthritis, Nature Immunology, Nat Immunol.
2021 Jan;22(1):10-18.
Myles J.
Lewis et al, Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes,, Cell Reports 28, 2455–2470
